Novartis Ag (NVS) Cash from Investing Activities (2009 - 2026)

Novartis Ag has reported Cash from Investing Activities for 18 years, with the latest figure at -$3.1 billion in Q2 2026.

• Quarterly Cash from Investing Activities fell 38.43% year-over-year to -$3.1 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$8.3 billion (down 30.02% YoY) and the FY2025 annual result came in at -$4.9 billion, up 35.09% from the prior year.
• Cash from Investing Activities retreated to -$3.1 billion in Q2 2026 per NVS's latest filing, from -$2.1 billion in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $330.0 million in Q1 2025 and troughed at -$11.6 billion in Q2 2022.
• A 5-year average of -$2.4 billion and a median of -$1.5 billion in 2023 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2022 and 2025: Cash from Investing Activities sank 11965.31% in 2022, then surged 136.71% in 2025.
• Over 5 years, Cash from Investing Activities stood at -$11.6 billion in 2022, then soared by 91.74% to -$960.0 million in 2023, then plunged by 327.71% to -$4.1 billion in 2024, then soared by 48.76% to -$2.1 billion in 2025, then slumped by 47.58% to -$3.1 billion in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered -$3.1 billion, -$2.1 billion, and -$860.0 million for Q2 2026, Q4 2025, and Q3 2025 respectively.